Stanford scientists and their collaborators have discovered a molecule that initiates the final, crucial step in a type of cell death.

Gut bacteria able to digest seaweed can outcompete native bacteria in the large intestine of nori-fed mice, according to Stanford scientists. Favoring one species over others in the gut could help advance precision health.

The California Institute for Regenerative Medicine awarded Stanford researcher Crystal Mackall a grant to study immune cells genetically modified to attack two proteins on leukemia and lymphoma cells.

Stanford scientists, focusing on chemical adjuncts affixed to DNA-associated proteins, found that these markings become more diverse with age.

In mice, a fatal brainstem tumor was cleared by injecting it with engineered T cells that recognized the cancer and targeted it for destruction. The Stanford discovery is moving to human trials.

The two-day event will highlight the latest research by top scientists on technologies and analytic methods geared toward studying human immunology.

In a clinical trial, participants were given an antibody to CD117, a cell surface marker, in an effort to wipe out their defective blood stem cells without high-risk chemotherapy or radiation.

Many infectious diseases, including malaria, are marked by cyclical ups and downs. David Schneider takes a creative approach to making sense of those ups and downs.

Activating T cells in tumors eliminated even distant metastases in mice, Stanford researchers found. Lymphoma patients are being recruited to test the technique in a clinical trial.

Stanford scientists have developed a biochemical screen that identifies molecules critical to immunotherapy for a host of diseases, including cancer.